Gibson, Dunn & Crutcher, White & Case top MEA legal advisers in Q1-Q3 2025
Gibson, Dunn & Crutcher and White & Case have emerged as the foremost legal advisers for mergers and acquisitions (M&A) …
Gibson, Dunn & Crutcher and White & Case have emerged as the foremost legal advisers for mergers and acquisitions (M&A) …
MSD’s antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown promising efficacy during an early-stage trial in heavily pretreated colorectal cancer. Thus …
Annex 1 regulations refer to a set of guidelines from the European Medicines Agency (EMA) for the manufacture of sterile …
At the 129th Annual Meeting of the American Academy of Ophthalmology (AAO) 2025 in Orlando, Florida, EyePoint Pharmaceuticals presented updates …
Merck & Co (MSD) has broken ground on its new pharmaceutical manufacturing Centre of Excellence in Virginia, US, amid looming …
H Lundbeck and Contera Pharma have announced a research partnership aimed at expediting the discovery as well as development of …
GlobalData estimates suggest that, across seven of the world’s major pharmaceutical markets - the US, the big five in Europe …
Developing oncology medications is a complicated and costly process. While clinical trial designs have improved, these trials still face difficulties …
The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with …
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease …
Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous …
The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …
The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost therapeutic intervention options …
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase …
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results …